Key Points
BRUSSELS, Nov 6 (Reuters) - A major pharmaceutical rules overhaul, proposed by the European Commission in April, could see Europe's share in global research and development contract by a third to 21% by 2040 translating to 2 billion euros ($2.15 billion) per year in lost investment, industry group EFPIA said on Monday.. The European Federation of Pharmaceutical Industries and Associations (EFPIA) says the Commission has not conducted a competitiveness impact assessment and if the new rules become law, they would accelerate the negative innovation trend in the EU and hit small and medium-sized enterprises the hardest...
"Any changes to our incentives system would equally affect EU-based and foreign-based companies which bring medicines to the EU and, therefore, it would not put EU firms at a disadvantage," an EU Commission spokesperson said.. Medication was the single biggest contributor to the EUs trade surplus, with 235 billion euro ($252.13 billion) worth of exports in 2021...
When you launch a product, you have a negative profit contribution because you invest more in marketing, sales...it's really easy the last few years that you recoup your investment," Jorgensen said.. Novo Nordisk, a Danish firm, has become the Europe's most valuable listed company since it launched game-changing weight loss and diabetes drugs, Wegovy and Ozempic..
You might be interested in
EU seeks revised GMO rules to loosen curbs on gene-edited crops
05, Jul, 23The European Commission proposed a revision of its rules on genetically modified organisms (GMOs) on Wednesday to provide some loosening of restrictions for plants resulting from newer gene-editing technology.
Microsoft’s OpenAI ties face potential EU merger investigation
09, Jan, 24The European Commission said on Tuesday that it’s examining whether Microsoft’s investment in OpenAI might be reviewable under the bloc’s merger rules